Skip to content

Study · Randomized controlled trial · n = 1,344 · 2019

4 results

GnRH agonists to sustain the luteal phase in antagonist IVF cycles: a randomized prospective trial.

Fusi FM, Brigante CM, Zanga L, Mignini Renzini M, Bosisio C, Fadini R

Reproductive biology and endocrinology : RB&E29 Nov 2019Cited by 6 (Europe PMC)

PMID31783862 (opens in a new tab)PMCIDPMC6884808 (opens in a new tab)DOI10.1186/s12958-019-0543-2 (opens in a new tab)PepBankPUB-31783862
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

BackgroundThe addition of a GnRH analogue to the luteal phase in in vitro fertilization programs has been seldom proposed due to the presence of GnRH receptors in the endometrium. The aim of the study was to evaluate the effect of triptorelin addition in short antagonist cycles, compared to cycles where the only supplementation was progesterone.MethodsThe primary objective of this study was the study of the effect of Triptorelin addiction during the luteal phase on the live birth rate. Secondary objectives of efficacy were pregnancy rates and implantation rates, as well as safety in terms of OHSS risks. The study was a prospective, randomized, open study, performed in two independent Centers from July 2013 to October 2015. Patients were divided into three groups: a) Regular antagonist protocol, with only luteal progesterone; b) Antagonist protocol with luteal triptorelin as multiple injections, c) Antagonist protocol with luteal triptorelin as single bolus. Descriptive statistics were obtained for all the parameters. Mean and standard deviation were used for all quantitative parameters. Differences between percentages were studied using Chi-square test generalized to the comparison of several proportions.ResultsA total number of 1344 patients completed the study, 786 under the age of 35 years, and 558 over 35 years. It was observed an increase of positive HCG results, Clinical pregnancy rates and Delivery rates when triptorelin was added in the luteal phase, irrespective whether as a single bolus or five injections. This increase was statistically significant both for pregnancy rates and delivery rates. The statistic difference between pregnancies and deliveries obtained with or without luteal triptorelin reached p < 0,01. No increase of OHSS risk was observed.ConclusionsFrom this large study it appears that the concept of luteal phase supplementation should be revisited. From our study it appears that triptorelin addition to the luteal phase of antagonist cycles, either as a single bolus or using multiple injections, is a good tool to optimize ART results.Trial registrationThe study was approved by the Ethics Committee of Provincia di Bergamo (n 1203/2013).
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In antagonist IVF cycles, luteal triptorelin significantly increased clinical pregnancy rates versus progesterone alone, with single or multiple injections.

    In plain wordsIn antagonist IVF cycles, luteal triptorelin increased clinical pregnancy rates compared with progesterone alone.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseClinical pregnancy rate
    Study

    n = 1,344

    Comparator
    Luteal progesterone without triptorelin
    Analysis
    Secondary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It was observed an increase of positive HCG results, Clinical pregnancy rates and Delivery rates when triptorelin was added in the luteal phase, irrespective whether as a single bolus or five injections.
    4 context sentences
    Summary · context
    This increase was statistically significant both for pregnancy rates and delivery rates.
    Summary · context
    Secondary objectives of efficacy were pregnancy rates and implantation rates, as well as safety in terms of OHSS risks.
    Summary · context
    The study was a prospective, randomized, open study, performed in two independent Centers from July 2013 to October 2015.
    Summary · context
    Patients were divided into three groups: a) Regular antagonist protocol, with only luteal progesterone; b) Antagonist protocol with luteal triptorelin as multiple injections, c) Antagonist protocol with luteal triptorelin as single bolus.
  2. 02HumanRandomized controlled trialSafety outcome

    In antagonist IVF cycles, luteal triptorelin did not increase OHSS risk compared with progesterone alone.

    In plain wordsIn antagonist IVF cycles, luteal triptorelin did not increase ovarian hyperstimulation risk compared with progesterone alone.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeOHSS risk
    Study

    n = 1,344

    Comparator
    Luteal progesterone without triptorelin
    Analysis
    Secondary
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No increase of OHSS risk was observed.
    3 context sentences
    Summary · context
    Secondary objectives of efficacy were pregnancy rates and implantation rates, as well as safety in terms of OHSS risks.
    Summary · context
    The study was a prospective, randomized, open study, performed in two independent Centers from July 2013 to October 2015.
    Summary · context
    Patients were divided into three groups: a) Regular antagonist protocol, with only luteal progesterone; b) Antagonist protocol with luteal triptorelin as multiple injections, c) Antagonist protocol with luteal triptorelin as single bolus.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In antagonist IVF cycles, luteal triptorelin increased positive HCG results versus progesterone alone, with single or multiple injections.

    In plain wordsIn antagonist IVF cycles, luteal triptorelin increased positive HCG results compared with progesterone alone.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreasePositive HCG results
    Study

    n = 1,344

    Comparator
    Luteal progesterone without triptorelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It was observed an increase of positive HCG results, Clinical pregnancy rates and Delivery rates when triptorelin was added in the luteal phase, irrespective whether as a single bolus or five injections.
    2 context sentences
    Summary · context
    The study was a prospective, randomized, open study, performed in two independent Centers from July 2013 to October 2015.
    Summary · context
    Patients were divided into three groups: a) Regular antagonist protocol, with only luteal progesterone; b) Antagonist protocol with luteal triptorelin as multiple injections, c) Antagonist protocol with luteal triptorelin as single bolus.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In antagonist IVF cycles, luteal triptorelin significantly increased delivery rates versus progesterone alone, with single or multiple injections.

    In plain wordsIn antagonist IVF cycles, luteal triptorelin increased delivery rates compared with progesterone alone.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseDelivery rate
    Study

    n = 1,344

    Comparator
    Luteal progesterone without triptorelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It was observed an increase of positive HCG results, Clinical pregnancy rates and Delivery rates when triptorelin was added in the luteal phase, irrespective whether as a single bolus or five injections.
    4 context sentences
    Summary · context
    This increase was statistically significant both for pregnancy rates and delivery rates.
    Summary · context
    The primary objective of this study was the study of the effect of Triptorelin addiction during the luteal phase on the live birth rate.
    Summary · context
    The study was a prospective, randomized, open study, performed in two independent Centers from July 2013 to October 2015.
    Summary · context
    Patients were divided into three groups: a) Regular antagonist protocol, with only luteal progesterone; b) Antagonist protocol with luteal triptorelin as multiple injections, c) Antagonist protocol with luteal triptorelin as single bolus.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.